Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3949825 | 1.00 | CNR2 (0.83) | CNR2CNR1 | |
| SCHEMBL13794063 | 1.00 | CNR2 (0.83) | CNR2CNR1 | |
| SCHEMBL14367354 | 0.91 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL14367352 | 0.91 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL13794576 | 0.91 | CNR2 (0.83) | CNR2CNR1 | |
| SCHEMBL3949248 | 0.91 | CNR2 (0.83) | CNR2CNR1 | |
| SCHEMBL3950521 | 0.91 | CNR2 (0.83) | CNR2CNR1 | |
| SCHEMBL14367337 | 0.90 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL13794058 | 0.90 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL5624065 | 0.90 | CNR2 (1.00) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058302-A1 | Sulfamoyl Benzamides and Methods of Their Use | CALIXA THERAPEUTICS, INC. | 2008-03-06 | — | — | US | claimed |
| US-7544676-B2 | Sulfamoyl benzamides and methods of their use | ADOLOR CORPORATION (US) | 2009-06-09 | — | — | US | disclosed |
| US-20080058302-A1 | Sulfamoyl Benzamides and Methods of Their Use | CALIXA THERAPEUTICS, INC. | 2008-03-06 | — | — | US | disclosed |
| WO-2007058960-A1 | SULFAMOYL BENZAMIDES AS CANNABINOID RECEPTOR MODULATORS | ADOLOR CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058302-A1 | Sulfamoyl Benzamides and Methods of Their Use | CNR2, TRPV1, CNR1 | CNR2 1/4885CNR1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.